13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001779763
Total reported value
$874.7M
$874.7M
28 檔
32.9%
According to the latest 13F quarterly dataset, Iron Triangle Partners LP managed an equity portfolio of $874.7M at the end of Q1 2024, spanning 28 distinct U.S. exchange-listed positions.
During Q1 2024, Iron Triangle Partners LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including ACHC, DXCM, ICLR) accounted for 32.9% of total reported equity market value during Q1 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ACHC | Acadia Healthcare Co Inc | Stock-Other | 7.33% | — | +13.99% | |
| 2 | DXCM | Dexcom Inc | Stock-Healthcare | 6.70% | -8.13% | EXIT | |
| 3 | ICLR | ICON Public Limited Company | Stock-Healthcare | 5.19% | — | -12.64% | |
| 4 | ABBV | Abbvie Inc | Stock-Healthcare | 5.15% | -6.60% | EXIT | |
| 5 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 5.08% | +6.12% | NEW | |
| 6 | EXK | Exact Sciences CORP | Stock-Materials | 4.95% | -3.89% | EXIT | |
| 7 | WST | West Pharmaceutical Services | Stock-Healthcare | 4.85% | -2.61% | EXIT | |
| 8 | ALGN | Align Technology Inc | Stock-Healthcare | 4.77% | — | — | |
| 9 | ILMN | Illumina Inc | Stock-Healthcare | 4.65% | — | +50.34% | |
| 10 | BRKR | Bruker CORP | Stock-Healthcare | 4.49% | +4.28% | NEW | |
| 11 | GKOS | Glaukos CORP | Stock-Healthcare | 4.15% | -3.98% | EXIT | |
| 12 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 4.00% | — | +113.07% | |
| 13 | BKD | Brookdale Senior Living Inc | Stock-Other | 3.99% | +0.89% | +21.37% | |
| 14 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 3.31% | — | — | |
| 15 | FTRE | Fortrea Holdings Inc | Stock-Healthcare | 3.25% | +3.92% | NEW | |
| 16 | ELAN | Elanco Animal Health Inc | Stock-Healthcare | 3.18% | — | -36.41% | |
| 17 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 3.11% | -2.62% | EXIT | |
| 18 | AVTR | Avantor Inc | Stock-Healthcare | 3.01% | — | — | |
| 19 | SWAVUSD | Shockwave Medical Inc | Stock-Other | 2.66% | — | — | |
| 20 | SDGR | Schrodinger Inc | Stock-Other | 2.39% | — | +84.24% | |
| 21 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 2.37% | — | — | |
| 22 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 2.20% | — | — | |
| 23 | CYTK | Cytokinetics Inc | Stock-Healthcare | 2.15% | — | — | |
| 24 | MCK | Mckesson CORP | Stock-Healthcare | 2.06% | — | -53.23% | |
| 25 | OSCR | Oscar Health Inc - Class A | Stock-Healthcare | 2.03% | — | -34.98% | |
| 26 | ARGX | Argenx Se - Adr | Stock-Healthcare | 1.81% | -1.04% | EXIT | |
| 27 | MASS | 908 Devices Inc | Stock-Other | 0.80% | — | -19.00% | |
| 28 | ✓ | Nyxoah S A | Stock-Other | 0.35% | — | — |
According to official SEC Form 13F filings, Iron Triangle Partners LP reported a total U.S. public equity portfolio value of $874.7M across 28 disclosed positions in Q1 2024.
During Q1 2024, Iron Triangle Partners LP's top holdings by market value included ACHC (7.3%)、DXCM (6.7%)、ICLR (5.2%). The largest single position, ACHC, represented 7.3% of total portfolio value.
In Q1 2024, Iron Triangle Partners LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.